Displaying drugs 11301 - 11325 of 11775 in total
Nemolizumab
Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
Investigational
Matched Description: … Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study …
Flutriciclamide F-18
Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques).
Investigational
Matched Description: … Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation …
Cenersen
Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)).
Investigational
Matched Description: … Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea® (Cenersen) in Transfusion …
Valomaciclovir stearate
Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster).
Investigational
Matched Description: … Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB …
Fisogatinib
Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).
Investigational
Matched Description: … Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib( …
TPIV 200
TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Investigational
Matched Description: … TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage …
DCN-tCRK
DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
Investigational
Matched Description: … DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal …
VXA-CoV2-1
VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant . This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell responses to both...
Investigational
Matched Description: … a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. ... VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses …
Tasosartan
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
KIN-3248
KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. While effective, disease progression may occur 6 to 8 months...
Investigational
Matched Description: … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors ( …
Zinc mesoporphyrin
Investigational
Vatalanib
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Investigational
Matched Description: … Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial …
Mito-4509
Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
Investigational
Matched Description: … Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. …
Filanesib
Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigational
Matched Description: … Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in …
PF-06882961
PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Description: … PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy …
Leuvectin
Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE).
Investigational
Matched Description: … Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl …
Hemoximer
Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.
Investigational
Matched Description: … Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering …
CDX-6512
CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]
Investigational
Matched Description: … CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. …
Benapenem
Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis (AP)).
Investigational
Matched Description: … Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety …
Forimtamig
Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … Forimtamig is under investigation in clinical trial NCT06055075 (A Study Evaluating Safety, Tolerability …
Washed Microbiota Transplantation
Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn’s disease, and ulcerative colitis. Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes microfiltration through an automatic...
Investigational
Matched Description: … microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a ... Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes …
4-Methyl-2,5-dimethoxyamphetamine
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Experimental
Illicit
Matched Description: … A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and …
Gemcabene
Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
Investigational
Matched Description: … Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides …
GW 597599
GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced vomiting; functional dyspepsia; depression and anxiety.
Investigational
Matched Description: … GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced …
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Matched Description: … ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment …
Displaying drugs 11301 - 11325 of 11775 in total